Research and Scholarship

Patient-Reported Outcomes With Belantamab Mafodotin Treatment in Patients With Triple-Class Refractory Multiple Myeloma

Rakesh Popat,(1) BSc, MBBS, MRCP, FRCPath, PhD, Sagar Lonial,(2) MD, FACP, Peter M. Voorhees,(3) MD, Simona Degli Esposti,(4) MD, Boris Gorsh,(5a) PharmD, Ira Gupta,(5a) MD, Joanna Opalinska,(5) PhD, Sandhya Sapra,(5) PhD, Trisha Piontek,(5) BS, RN, Zangdong He,(5) PhD, David Kleinman,(6) MD, MBA, Debra Schaumberg,(7) SCD, OD, MPH, Antoine Regnault,(8) PhD, Juliette Meunier,(8) MSc, and Laurie Eliason,(5a) MPH

Authors’ disclosures of conflicts of interest are found at the end of this article.

From (1)NIHR University College London Hospitals Clinical Research Facility, University College London Hospitals NHS Foundation Trust, London, UK; (2)Emory University, Winship Cancer Institute, Atlanta, Georgia, USA; (3)Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA; (4)NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK; (5)GSK, Upper Providence, Pennsylvania, USA; (6)Flaum Eye Institute, University of Rochester, Rochester, New York, USA; (7)University of Utah School of Medicine, Department of Ophthalmology & Visual Sciences, Salt Lake City, Utah, USA; (8)Modus Outcomes, Lyon, France (a)At time of study. Correspondence to: Sandhya Sapra, PhD, GSK, 1250 S Collegeville Road, Upper Providence, PA 19426 E-mail: sandhya.j.sapra@gsk.com

ABSTRACT

In the randomized phase II DREAMM-2 study, single-agent belantamab mafodotin demonstrated deep and durable responses and a manageable safety profile in triple-class refractory relapsed/refractory multiple myeloma (RRMM). We present patient-reported outcomes (PROs) from this study for patients treated with the approved dose of belantamab
mafodotin (2.5 mg/kg q3w). Disease and treatment-related symptoms, health-related quality of life (HRQOL), functioning, and patient-reported ocular changes were assessed using questionnaires (European Organisation for Research and Treatment of Cancer Quality of Life questionnaires EORTC-QLQ-C30 and EORTC-QLQ-MY20, Ocular Surface Disease Index [OSDI], and the National Eye Institute Visual Functioning Questionnaire 25 [NEI VFQ-25]) at baseline, during treatment (every 3 or 6 weeks), and at the end of treatment (EOT). Eye examinations were conducted at baseline, prior to each treatment cycle, and at EOT. Patients reported ocular symptoms in the OSDI and NEI VFQ-25 questionnaires, with the median time to worst severity of 45 to 64 days depending on symptoms considered. Some limitations in driving and reading were reported. Ocular symptoms were improved and median time to recovery was 23.5 to 44.0 days. EORTC-QLQ-C30 data suggest core MM symptoms (including fatigue and pain), overall HRQOL, and patient functioning were maintained while patients continued belantamab mafodotin treatment, even if meaningful worsening of vision-related symptoms occurred. These PRO results, together with the clinical efficacy of belantamab mafodotin, support its use in patients with RRMM and further evaluation of its use at earlier lines of therapy.

For access to the full length article, please sign in.